Motif Bio PLC Motif selected to present at Biotech Showcase
07 Dicembre 2015 - 8:00AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
07 December 2015
07 December 2015
Motif Bio plc
("Motif" or the "Company")
Motif selected to present at Biotech Showcase, San Francisco,
January 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, today
announced that the Company has been selected to present at the
Biotech Showcase 2016, San Francisco, on:
Monday, January 11, 2016 at 1400 PST
Track: D - Powell (3rd Floor)
Biotech Showcase, which runs alongside the largest healthcare
investor event of the year - the JP Morgan Annual Healthcare
Conference - is an investor and partnering conference dedicated to
providing private and public life sciences companies an opportunity
to meet with investors and pharmaceutical executives from around
the world.
Graham Lumsden, Chief Executive Officer at Motif, said: "Being
selected to present at such an important event is recognition of
Motif's success to date and future potential. Members of the Motif
Leadership Team will be in San Francisco to meet pharma and biotech
investors and partners attending the Biotech Showcase and JP Morgan
conference."
For further information please contact
Enquiries
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
David Huang (Chief Medical Officer)
www.motifbio.com
Zeus Capital Limited (NOMINATED
ADVISER and BROKER)
Phil Walker/Dan Bate +44 (0) 20
Dominic Wilson 3829 5000
Northland Capital Partners Limited
(BROKER)
Patrick Claridge/ David Hignell +44 (0) 20
John Howes/ Mark Treharne (Broking) 7382 1100
+49 (0) 89
MC Services AG (TRADE PR) 210 2280
Raimund Gabriel +44 (0) 207
Shaun Brown 148 5998
Plumtree Capital Limited (FINANCIAL
ADVISER) +44 (0) 207
Stephen Austin 183 2493
Yellow Jersey PR Limited (FINANCIAL
PR)
Charles Goodwin +44 (0) 7747
Dominic Barretto 788 221
Notes to Editors:
Motif is a clinical-stage biopharmaceutical company,
specialising in the development of novel antibiotics that are
designed to be effective against serious and life-threatening
infections caused by multi-drug resistant bacteria. Our lead
product candidate, iclaprim, is being developed for the treatment
of the most common and serious bacterial infections such as acute
bacterial skin and skin structure infections (ABSSSI) and hospital
acquired bacterial pneumonia (HABP), including those caused by
resistant strains such as MRSA (methicillin-resistant
Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on
track to be completed in 2017 and if approved, iclaprim could be
ready for commercialization in 2018. The Company is in discussions
with pharmaceutical companies and universities to build a pipeline
of innovative antibiotics targeting Gram-positive and Gram-negative
bacteria. For additional information about Motif please visit
www.motifbio.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGGGWPUPAUBA
(END) Dow Jones Newswires
December 07, 2015 02:00 ET (07:00 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024